Corinna Weber‐Schoendorfer

Charité - Universitätsmedizin Berlin

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Christof Schaefer

Humboldt-Universität zu Berlin

Reinhard Meister

Berliner Hochschule für Technik

Christof Schaefer

Charité - Universitätsmedizin Berlin

Maria Hoeltzenbein

Humboldt-Universität zu Berlin

Angela Kayser

Charité - Universitätsmedizin Berlin

Orna Diav‐Citrin

Israel Ministry of Health

Evelin Beck

Charité - Universitätsmedizin Berlin

Svetlana Shechtman

Israel Ministry of Health

Stephanie Padberg

Humboldt-Universität zu Berlin

Alice Panchaud

University of Bern

Cooperative Institutions

Charité - Universitätsmedizin Berlin

Freie Universität Berlin

Humboldt-Universität zu Berlin

University Hospital of Lausanne

University of Lausanne

Berliner Hochschule für Technik

Tel Aviv University

Institute of Social and Preventive Medicine

Hebrew University of Jerusalem

Israel Ministry of Health

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Pregnancy outcome after first trimester use of methyldopa: A prospective observational cohort study

Reproductive Toxicology (2017)

Maria Hoeltzenbein Evelin Beck Anne‐Katrin Fietz Juliane Wernicke Sandra Zinke

Formula feeding

10.1016/j.reprotox.2017.06.004

Cite

Citations (0)

Lamotrigine during lactation

Reproductive Toxicology (2008)

Stephanie Padberg Corinna Weber‐Schoendorfer Christof Schaefer

Premenstrual dysphoric disorder

Agoraphobia

Depression

Specific phobia

Neuropsychiatry

Cross-sectional study

10.1016/j.reprotox.2008.05.038

Cite

Citations (3)

Pregnancy outcome following use of levodopa, pramipexole, ropinirole, and rotigotine for restless legs syndrome during pregnancy: a case series

European Journal of Neurology (2012)

M Dostál Corinna Weber‐Schoendorfer Jan Sobesky Christof Schaefer

Background Restless legs syndrome ( RLS ) is related to parity, and its symptoms may worsen during pregnancy. Treatment with levodopa or dopamine agonists is the first‐line therapy for RLS ; however, there are limited data on treatment in pregnancy. We therefore assessed the safety of levodopa, pramipexole, rotigotine, and ropinirole in pregnancy. Methods Prospective documentation of pregnancies exposed to levodopa, pramipexole, rotigotine, and ropinirole between 1998 and 2011 was evaluated as to their outcome (teratogenicity or fetotoxicity) by the B erlin I nstitute for C linical T eratology and D rug R isk A ssessment in P regnancy. Results We were able to complete 59 pregnancy outcomes exposed to RLS pharmacotherapy. For specific treatments, the numbers of exposed pregnancies/live born children/spontaneous abortions/induced abortions/malformations were as follows: levodopa only: 38/29 (one pair of twins)/3/7/3; pramipexole only: 12/9/3/0/0; rotigotine only: 2/2/0/0/0; ropinirole only: 3/2/0/1/0; levodopa combined with pramipexole: 3/3/0/0/0; levodopa combined with ropinirole: 1/1/0/0/0. No major birth defects were found with any RLS treatment, and three infants exposed to levodopa had minor anomalies. Conclusions In our small prospective case series, there was no increased risk above baseline for major malformations or other adverse outcomes for levodopa and pramipexole. If necessary, levodopa treatment may be considered as an alternative to cabergoline, for which safety has been well documented in pregnancy.

Ropinirole

Pramipexole

Rotigotine

Cabergoline

Restless Legs Syndrome

10.1111/ene.12001

Cite

Citations (56)

Monoclonal antibody therapy during pregnancy—Experience of the Berlin teratology information service

Reproductive Toxicology (2008)

Corinna Weber‐Schoendorfer Christof Schaefer

10.1016/j.reprotox.2008.05.050